VistaGen Therapeutics shares are trading lower after the company announced results from its exploratory Phase 2A study of PH80 in women diagnosed with menopausal hot flashes.
Portfolio Pulse from Benzinga Newsdesk
VistaGen Therapeutics announced results from its exploratory Phase 2A study of PH80 in women diagnosed with menopausal hot flashes, causing its shares to trade lower.
June 07, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
VistaGen Therapeutics shares are trading lower after announcing results from its Phase 2A study of PH80 in women with menopausal hot flashes.
The announcement of the Phase 2A study results for PH80 directly impacts VistaGen Therapeutics' stock price, as it reflects the progress of the company's product development. The negative market reaction suggests that the results may not have met investor expectations, leading to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100